Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

2.

When BCG is not effective in treating bladder cancer, Oncolytic Virus exhibits high response rates.

3.

Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?

4.

Urinary tract cancer prediction models with high sensitivity and specificity

5.

Mapping lifelong chronic health risks for childhood cancer survivors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot